Shares of Aurobindo Pharma surged as much as 7% today after the company reported a 26% increase in consolidated net profit in the second quarter which ended in September. After a green opening, the stock further jumped to ₹863.60 on the BSE.
The company had posted a consolidated net profit of ₹639.53 crore in the same quarter last fiscal year, Aurobindo Pharma said in a regulatory filing.
Consolidated total revenue from operations during the period under review stood at ₹6,483.44 crore as against ₹5,600.47 crore in the corresponding quarter last fiscal, it added. At 12:30 pm, Aurobindo Pharma shares were trading 5% higher as compared to a 1% gain in Nifty pharma index.
Aurobindo Pharma said US revenue in Q2FY21 witnessed a growth of 12.5% YoY to ₹3,189.8 crore, accounting 49.2% of consolidated revenue. On a constant currency basis, revenue grew by 6.6% YoY to $430 million.
In Q2, the company said it filed 24 ANDAs (Abbreviated new drug application) with USFDA (Unites states food and drug administration) including 10 injectables and received final approval for 10 ANDAs in Q2FY21. The company has launched 17 products during the quarter including 6 injectables.
